Antiviral Treatments

Clinics in Chest Medicine

Volumn 38, Issue 1, 2017, Pages 139-153

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Influenza; Neuraminidase inhibitor; Respiratory syncytial virus (RSV); Respiratory virus; Ribavirin

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ASVASIRAN; CIDOFOVIR; DAS 181; FAVIPIRAVIR; LANINAMIVIR; LANINAMIVIR OCTANOATE; LUMICITABINE; MUSCARINIC M2 RECEPTOR; NITAZOXANIDE; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; PLACEBO; PRESATOVIR; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ANXIETY; CONCENTRATION LOSS; CONGESTIVE HEART FAILURE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY POWDER INHALER; FEVER; HEADACHE; HEPATITIS C; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA A VIRUS; INFLUENZA B; INSOMNIA; LIVER DYSFUNCTION; LOWER RESPIRATORY TRACT INFECTION; NAUSEA; NEPHROTOXICITY; ORTHOSTATIC HYPOTENSION; PARAINFLUENZA VIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VERTIGO; VIRAL GASTROENTERITIS; VIRUS STRAIN; VOMITING; DRUG EFFECTS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA, HUMAN; PATHOGENICITY; PATHOLOGY; RESPIRATORY TRACT INFECTIONS;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA, HUMAN; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS;

EID: 85008215967     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2016.11.008     Document Type: Review

References (125)

1. 1 Limaye, A.P., Boeckh, M., CMV in critically ill patients: pathogen or bystander?. Rev Med Virol 20 (2010), 372–379.
2. 2 Luyt, C.E., Combes, A., Trouillet, J.L., et al. Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome. Presse Med 40 (2011), e561–e568.
3. 3 Travi, G., Pergam, S.A., Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J Intensive Care Med 29 (2014), 200–212.
4. 4 Hayden, F.G., Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 7:Suppl 1 (2013), 63–75.
5. 5 Hurt, A.C., Hui, D.S., Hay, A., et al. Overview of the 3rd isirv-Antiviral Group Conference–advances in clinical management. Influenza Other Respir Viruses 9 (2015), 20–31.
6. 6 McKimm-Breschkin, J.L., Fry, A.M., Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res 129 (2016), 21–38.
7. 7 Chan, J.F., Chan, K.H., Kao, R.Y., et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 67 (2013), 606–616.
8. 8 de Wilde, A.H., Jochmans, D., Posthuma, C.C., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial Agents Chemother 58 (2014), 4875–4884.
9. 9 Hay, A.J., Wolstenholme, A.J., Skehel, J.J., et al. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4 (1985), 3021–3024.
10. 10 Pinto, L.H., Holsinger, L.J., Lamb, R.A., Influenza virus M2 protein has ion channel activity. Cell 69 (1992), 517–528.
11. 11 Hay, A.J., Zambon, M.C., Wolstenholme, A.J., et al. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 18:Suppl B (1986), 19–29.
12. 12 Alves Galvao, M.G., Rocha Crispino Santos, M.A., Alves da Cunha, A.J., Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev(1), 2012 CD002745.
13. 13 Hsu, J., Santesso, N., Mustafa, R., et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 156 (2012), 512–524.
14. 14 Kaiser, L., Hayden, F.G., Hospitalizing influenza in adults. Swartz, M.N., (eds.) Current clinical topics in infectious diseases, 1999, Blackwell Science, Malden (MA), 112–134.
15. 15 Fiore, A.E., Fry, A., Shay, D., et al. Antiviral agents for the treatment and chemoprophylaxis of influenza –- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60 (2011), 1–24.
16. 16 Aoki, F.Y., Sitar, D.S., Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14 (1988), 35–51.
17. 17 Hayden, F.G., Aoki, F.Y., Amantadine, rimantadine and related agents. Barriere, S.L., (eds.) Antimicrobial therapy and vaccines, 1999, Williams and Wilkins, Baltimore (MD), 1344–1365.
18. 18 Hayden, F.G., Minocha, A., Spyker, D.A., et al. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrobial Agents Chemother 28 (1985), 216–221.
19. 19 Keyser, L.A., Karl, M., Nafziger, A.N., et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 160 (2000), 1485–1488.
20. 20 Wills, R.J., Update on rimatadine's clinical pharmacokinetics. J Respir Dis 10 (1989), s20–s25.
21. 21 Colman, P.M., Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3 (1994), 1687–1696.
22. 22 Moscona, A., Neuraminidase inhibitors for influenza. N Engl J Med 353 (2005), 1363–1373.
23. 23 Kamali, A., Holodniy, M., Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infect Drug Resist 6 (2013), 187–198.
24. 24 Yamashita, M., Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother 21 (2010), 71–84.
25. 25 Watanabe, A., Chang, S.C., Kim, M.J., et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51 (2010), 1167–1175.
26. 26 Sugaya, N., Ohashi, Y., Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrobial Agents Chemother 54 (2010), 2575–2582.
27. 27 Koseki, N., Kaiho, M., Kikuta, H., et al. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. Influenza Other Respir Viruses 8 (2014), 151–158.
28. 28 Katsumi, Y., Otabe, O., Matsui, F., et al. Effect of a single inhalation of laninamivir octanoate in children with influenza. Pediatrics 129 (2012), e1431–e1436.
29. 29 Kashiwagi, S., Watanabe, A., Ikematsu, H., et al. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. J Infect Chemother 19 (2013), 740–749.
30. 30 Watanabe, A., A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother 19 (2013), 89–97.
31. 31 McClellan, K., Perry, C.M., Oseltamivir: a review of its use in influenza. Drugs 61 (2001), 263–283.
32. 32 He, G., Massarella, J., Ward, P., Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37 (1999), 471–484.
33. 33 Ison, M.G., Szakaly, P., Shapira, M.Y., et al. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther 17 (2012), 955–964.
34. 34 Baz, M., Abed, Y., Papenburg, J., et al. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 361 (2009), 2296–2297.
35. 35 Kaiser, L., Wat, C., Mills, T., et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163 (2003), 1667–1672.
36. 36 Acosta, E.P., Jester, P., Gal, P., et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis 202 (2010), 563–566.
37. 37 Kamal, M.A., Acosta, E.P., Kimberlin, D.W., et al. The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach. Clin Pharmacol Ther 96:3 (2014), 380–389.
38. 38 Kimberlin, D.W., Acosta, E.P., Prichard, M.N., et al. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis 207 (2013), 709–720.
39. 39 Whitley, R.J., Hayden, F.G., Reisinger, K.S., et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20 (2001), 127–133.
40. 40 Piedra, P.A., Schulman, K.L., Blumentals, W.A., Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 124 (2009), 170–178.
41. 41 Kumar, D., Michaels, M.G., Morris, M.I., et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 10 (2010), 521–526.
42. 42 Reid, G., Huprikar, S., Patel, G., et al. A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients. Transpl Infect Dis 15 (2013), 487–492.
43. 43 Lee, N., Ison, M.G., Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther 17 (2012), 143–157.
44. 44 Lee, N., Ison, M.G., Editorial commentary. “Late” treatment with neuraminidase inhibitors for severely ill patients with influenza: better late than never?. Clin Infect Dis 55 (2012), 1205–1208.
45. 45 Louie, J.K., Yang, S., Acosta, M., et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 55 (2012), 1198–1204.
46. 46 Muthuri, S.G., Venkatesan, S., Myles, P.R., et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2 (2014), 395–404.
47. 47 Lee, N., Hui, D.S., Zuo, Z., et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis 57 (2013), 1511–1519.
48. 48 South East Asia Infectious Disease Clinical Research Network, Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ, 346, 2013, f3039.
49. 49 Kumar, A., Viral clearance with standard or triple dose oseltamivir therapy in critically ill patients with pandemic (H1N1) 2009 influenza. 2013, ICAAC, Denver (CO), B-1470.
50. 50 Beigi, R.H., Han, K., Venkataramanan, R., et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol 204 (2011), S84–S88.
51. 51 Greer, L.G., Leff, R.D., Rogers, V.L., et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 204 (2011), S89–S93.
52. 52 Greer, L.G., Leff, R.D., Rogers, V.L., et al. Pharmacokinetics of oseltamivir in breast milk and maternal plasma. Am J Obstet Gynecol, 204, 2011, 524.e1-4.
53. 53 Toovey, S., Prinssen, E.P., Rayner, C.R., et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther 29 (2012), 826–848.
54. 54 Hoffman, K.B., Demakas, A., Erdman, C.B., et al. Neuropsychiatric adverse effects of oseltamivir in the FDA adverse event reporting system, 1999-2012. BMJ, 347, 2013, f4656.
55. 55 Lam, H., Jeffery, J., Sitar, D.S., et al. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. Ther Drug Monit 33 (2011), 699–704.
56. 56 Boltz, D.A., Aldridge, J.R. Jr., Webster, R.G., et al. Drugs in development for influenza. Drugs 70 (2010), 1349–1362.
57. 57 Chairat, K., Tarning, J., White, N.J., et al. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J Clin Pharmacol 53:2 (2012), 119–139.
58. 58 Kohno, S., Kida, H., Mizuguchi, M., et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrobial Agents Chemother 54 (2010), 4568–4574.
59. 59 Kohno, S., Yen, M.Y., Cheong, H.J., et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrobial Agents Chemother 55 (2011), 5267–5276.
60. 60 Kohno, S., Kida, H., Mizuguchi, M., et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrobial Agents Chemother 55 (2011), 2803–2812.
61. 61 Ison, M.G., Hui, D.S., Clezy, K., et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 18 (2013), 651–661.
62. 62 Ison, M.G., Fraiz, J., Heller, B., et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther 19 (2014), 349–361.
63. 63 de Jong, M.D., Ison, M.G., Monto, A.S., et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 59 (2014), e172–e185.
64. 64 Sugaya, N., Kohno, S., Ishibashi, T., et al. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrobial Agents Chemother 56 (2012), 369–377.
65. 65 Arya, V., Carter, W.W., Robertson, S.M., The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir. Clin Pharmacol Ther 88 (2010), 587–589.
66. 66 Thomas, B., Hollister, A.S., Muczynski, K.A., Peramivir clearance in continuous renal replacement therapy. Hemodialysis Int 14 (2010), 339–340.
67. 67 Centers for Disease Control and Prevention. Emergency use authorization of Peramivir IV: fact sheet for health care providers. 2009.
68. 68 Cass, L.M., Efthymiopoulos, C., Bye, A., Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36:Suppl 1 (1999), 1–11.
69. 69 Dunn, C.J., Goa, K.L., Zanamivir: a review of its use in influenza. Drugs 58 (1999), 761–784.
70. 70 Diggory, P., Fernandez, C., Humphrey, A., et al. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 322 (2001), 577–579.
71. 71 Marty, F.M., Man, C.Y., van der Horst, C., et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J Infect Dis 209 (2014), 542–550.
72. 72 Weller, S., Jones, L.S., Lou, Y., et al. Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment. Antimicrobial Agents Chemother 57 (2013), 2967–2971.
73. 73 Hedrick, J.A., Barzilai, A., Behre, U., et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19 (2000), 410–417.
74. 74 Lalezari, J., Campion, K., Keene, O., et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients - a pooled analysis of randomized controlled trials. Arch Intern Med 161 (2001), 212–217.
75. 75 Murphy, K.R., Eivindson, A., Pauksens, K., et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease - a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Invest 20 (2000), 337–349.
76. 76 Chan-Tack, K.M., Gao, A., Himaya, A.C., et al. Clinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States. J Infect Dis 207 (2013), 196–198.
77. 77 Duval, X., van der Werf, S., Blanchon, T., et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med, 7, 2010, e1000362.
78. 78 Wray, S.K., Gilbert, B.E., Knight, V., Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res 5 (1985), 39–48.
79. 79 Wray, S.K., Gilbert, B.E., Noall, M.W., et al. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 5 (1985), 29–37.
80. 80 Paroni, R., Del Puppo, M., Borghi, C., et al. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Pharmacol Ther Toxicol 27 (1989), 302–307.
81. 81 Chemaly, R.F., Torres, H.A., Munsell, M.F., et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 206 (2012), 1367–1371.
82. 82 Rodriguez, W.J., Hall, C.B., Welliver, R., et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 125 (1994), 129–135.
83. 83 Glanville, A.R., Scott, A.I., Morton, J.M., et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 24 (2005), 2114–2119.
84. 84 Shah, J.N., Chemaly, R.F., Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 117 (2011), 2755–2763.
85. 85 Marcelin, J.R., Wilson, J.W., Razonable, R.R., Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 16 (2014), 242–250.
86. 86 Ison, M.G., Respiratory viral infections in transplant recipients. Antivir Ther 12 (2007), 627–638.
87. 87 Ison, M.G., Adenovirus infections in transplant recipients. Clin Infect Dis 43 (2006), 331–339.
88. 88 Rossignol, J.F., Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 110 (2014), 94–103.
89. 89 Rossignol, J.F., La Frazia, S., Chiappa, L., et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 284 (2009), 29798–29808.
90. 90 Haffizulla, J., Hartman, A., Hoppers, M., et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 14 (2014), 609–618.
91. 91 Romark Laboratories, A phase III randomized double-blind placebo controlled trial to evaluate the efficacy and safety of nitazoxanide in the treatment of acute uncomplicated influenza. In: ClinicalTrials.gov [Internet], 2015, National Library of Medicine (US), Bethesda (MD) [cited 22 Dec 2015].
92. 92 Rossignol, J.F., Abu-Zekry, M., Hussein, A., et al. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 368 (2006), 124–129.
93. 93 Rossignol, J.F., El-Gohary, Y.M., Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 24 (2006), 1423–1430.
94. 94 Ison, M.G., Green, M., Practice ASTIDCo. Adenovirus in solid organ transplant recipients. Am J Transplant 9:Suppl 4 (2009), S161–S165.
95. 95 Dunning, J., Baillie, J.K., Cao, B., et al., International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis 14 (2014), 1259–1270.
96. 96 Atiee, G., Lasseter, K., Baughman, S., et al. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. J Clin Pharmacol 52 (2012), 1410–1419.
97. 97 Pukrittayakamee, S., Jittamala, P., Stepniewska, K., et al. An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. Antimicrobial Agents Chemother 55 (2011), 4050–4057.
98. 98 Nguyen, J.T., Hoopes, J.D., Le, M.H., et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One, 5, 2010, e9332.
99. 99 Seo, S., Englund, J.A., Nguyen, J.T., et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther 18 (2013), 377–386.
100. 100 Ison, M.G., Gnann, J.W. Jr., Nagy-Agren, S., et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 8 (2003), 183–190.
101. 101 Hung, I.F., To, K.K., Lee, C.K., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52 (2011), 447–456.
102. 102 Wang, C.H., Chung, F.T., Lin, S.M., et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med 42 (2014), 313–321.
103. 103 MDVI, LLC, Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults. In: ClinicalTrials.gov [Internet], 2015, National Library of Medicine (US), Bethesda (MD) [cited 21 Dec 2015].
104. 104 Malakhov, M.P., Aschenbrenner, L.M., Smee, D.F., et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrobial Agents Chemother 50 (2006), 1470–1479.
105. 105 Belser, J.A., Lu, X., Szretter, K.J., et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 196 (2007), 1493–1499.
106. 106 Triana-Baltzer, G.B., Gubareva, L.V., Klimov, A.I., et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One, 4, 2009, e7838.
107. 107 Triana-Baltzer, G.B., Gubareva, L.V., Nicholls, J.M., et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One, 4, 2009, e7788.
108. 108 Moss, R.B., Hansen, C., Sanders, R.L., et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 206 (2012), 1844–1851.
109. 109 Waghmare, A., Wagner, T., Andrews, R., et al. Successful treatment of parainfluenza virus respiratory tract infection with DAS181 in 4 immunocompromised children. J Pediatr Infect Dis Soc 4 (2015), 114–118.
110. 110 Chalkias, S., Mackenzie, M.R., Gay, C., et al. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl Infect Dis 16 (2014), 141–144.
111. 111 Drozd, D.R., Limaye, A.P., Moss, R.B., et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis 15 (2013), E28–E32.
112. 112 Guzman-Suarez, B.B., Buckley, M.W., Gilmore, E.T., et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transpl Infect Dis 14 (2012), 427–433.
113. 113 Salvatore, M., Satlin, M.J., Jacobs, S.E., et al. DAS181 for the treatment of parainfluenza virus infections in 16 hematopoietic stem cell transplant recipients at a single center. Biol Blood Marrow Transplant 22:5 (2016), 965–970.
114. 114 DeVincenzo, J.P., Whitley, R.J., Mackman, R.L., et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371 (2014), 711–722.
115. 115 Mackman, R.L., Sangi, M., Sperandio, D., et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem 58 (2015), 1630–1643.
116. 116 Samuel, D., Xing, W., Niedziela-Majka, A., et al. GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein. Antimicrobial Agents Chemother 59 (2015), 7109–7112.
117. 117 Gilead Sciences, Efficacy, pharmacokinetics, and safety of GS-5806 in hospitalized adults with respiratory syncytial virus (RSV) infection. In: ClinicalTrials.gov [Internet], 2015, National Library of Medicine (US), Bethesda (MD) [cited 2015 Nov 24].
118. 118 Gilead Sciences, GS-5806 in lung transplant (LT) recipients with respiratory syncytial virus (RSV) infection. In: ClinicalTrials.gov [Internet], 2015, National Library of Medicine (US), Bethesda (MD) [cited 2015 Nov 24].
119. 119 Tylden, G.D., Hirsch, H.H., Rinaldo, C.H., Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells. Antimicrobial Agents Chemother 59 (2015), 3306–3316.
120. 120 Gilead Sciences, GS-5806 in hematopoietic cell transplant recipients with respiratory syncytial virus (RSV) infection of the lower respiratory tract. In: ClinicalTrials.gov [Internet], 2015, National Library of Medicine (US), Bethesda (MD) [cited 2015 Nov 24].
121. 121 DeVincenzo, J.P., McClure, M.W., Symons, J.A., et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 373 (2015), 2048–2058.
122. 122 Parker, S., Crump, R., Foster, S., et al. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus. Antiviral Res 111 (2014), 42–52.
123. 123 DeVincenzo, J., Lambkin-Williams, R., Wilkinson, T., et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A 107 (2010), 8800–8805.
124. 124 Zamora, M.R., Budev, M., Rolfe, M., et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 183 (2011), 531–538.
125. 125 Gottlieb, J., Zamora, M.R., Hodges, T., et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant 35:2 (2016), 213–221.